Dr. Lachelle Dawn Weeks is a physician-scientist at Dana-Farber Cancer Institute and an Instructor of Medicine at Harvard Medical School. She received her MD and PhD degrees from Case Western Reserve University School of Medicine, completed Internal Medicine Residency at Brigham and Women’s Hospital and Hematology/Oncology Fellowship at Dana-Farber Cancer Institute. She currently leads the clinical and research efforts for clonal hematopoiesis (CH), a precursor to myeloid malignancies such as acute myeloid leukemia (AML), in the Center for Leukemia and Center for Prevention of Progression in the Division of Hematologic Malignancies at DFCI. Dr. Weeks is completing her postdoctoral research in the laboratory of Benjamin Ebert. Her studies integrate epidemiology and the analysis of large human genomic datasets to identify factors which influence risk of outcomes such as AML and inflammatory diseases in patients with CH. She uses the data generated to design novel clinical prognostic tools and develop rational intervention strategies to prevent negative outcomes in patients with CH. Dr. Weeks’s research is supported by the Harold Amos Medical Faculty Development Award from the American Society of Hematology/Robert Wood Johnson Foundation and the Edward P. Evans Foundation Dana-Farber/Harvard Cancer Center Fellowship.